Allegations include that Biohaven paid some healthcare providers over $100,000 to boost prescriptions of their migraine medication, Nurtec ODT, resulting in fraudulent claims to federal programs like Medicare and Medicaid.
This egregious scheme involved not just ordinary incentives, but also repeated, unnecessary educational programs that offered no real benefit to attendees, turning these events into mere facades for bribery.
This practice, aimed at increasing Nurtec ODT prescriptions, breached anti-kickback statutes designed to keep medical decisions free from financial influence.
